Condition
Lung Diseases
ClinicalTrials.gov condition label
Clinical trials
60 shownA Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILDNCT07333183 · 2025-12-23
RECRUITINGPALACE: Cemiplimab Trial According to ctDNA LevelsNCT06917573 · 2025-07-29
RECRUITINGPost-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung CancerNCT06758700 · 2025-02-07
RECRUITINGStudy of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.NCT06431633 · 2025-02-04
RECRUITINGClinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung CancerNCT07026110 · 2024-12-23
RECRUITINGEarly Intervention Strategies for Lung CancerNCT06988943 · 2024-06-25
RECRUITINGPET/CT GUIDED BIOPSY VERSUS CT GUIDED BIOPSY IN EVALUATION OF SUSPECTED LUNG NEOPLASMSNCT06923098 · 2023-07-01
RECRUITINGCough Capture as a Portal Into the LungNCT05854563 · 2023-03-28
RECRUITINGProspective Urban Rural Epidemiology StudyNCT03225586 · 2002-01-01
RECRUITINGLung Cancer Screening CT for FirefightersNCT06836414 · 2026-03-31
WITHDRAWNValidation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung CancerNCT07126626 · 2025-08-18
NOT_YET_RECRUITINGComparison of Double Lumen Tube Location Verification Techniques in Single Lung VentilationNCT07107893 · 2025-01-16
COMPLETEDLung Ultrasound in Critically Ill Obstetrics and Gynecological PatientsNCT06728709 · 2024-12-15
COMPLETEDSmall/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) StudyNCT06494241 · 2024-11-22
ACTIVE_NOT_RECRUITINGA Study of Mosliciguat in PH-ILDNCT06635850 · 2024-10-29
ACTIVE_NOT_RECRUITINGComparison Between Different Ways for Using Lidocaine During FBNCT06563050 · 2024-09-01
NOT_YET_RECRUITINGSPSIPB vs SAPB for Thoracoscopic SurgeryNCT06546839 · 2024-08-10
COMPLETEDFeasibility of a Youth-led NCD Risk Reduction Initiative in Selected Schools of Slums in Karachi, Pakistan: a Mixed-methods, pre-and Post-intervention StudyNCT06465771 · 2024-08-01
UNKNOWNOsimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCNCT06376084 · 2024-07-23
ACTIVE_NOT_RECRUITINGPulmonary Diffusing Capacity During Incremental Exercise in COPDNCT06505902 · 2024-07-15
COMPLETEDAdequacy Assessment of Bronchoscopic Biopsy Samples Using a Novel InstrumentNCT06499454 · 2024-07-01
UNKNOWNInvestigating Novel Strategies in Pediatric Immune Responses and Microbiome Environment: Comprehensive Lung Disease Investigation in Children.NCT06746077 · 2024-04-30
ENROLLING_BY_INVITATIONIndividualizing Treatment for Asthma in Primary CareNCT06272370 · 2024-02-01
COMPLETEDScreening for Lung Health by a Mobile DeviceNCT06232356 · 2023-12-30
UNKNOWNA Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLCNCT06177925 · 2023-12-10
UNKNOWNRCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory InfectionNCT06149494 · 2023-11-20
COMPLETEDObservational Bronchoscopy Video Data Collection Study With Adult PatientsNCT06465797 · 2023-11-08
COMPLETED3D-printed Reconstruction Automated Matching System Predicts Size of Double-lumen Tube: a Prospective Double-blinded Randomized Controlled TrialNCT05899270 · 2023-11-01
UNKNOWNReal World Registry for Use of the Ion Endoluminal SystemNCT06004440 · 2023-09-21
ACTIVE_NOT_RECRUITINGAnalysis of Lung Cancer Tissue With Spatial Frequency Domain ImagingNCT06549088 · 2023-08-07
ENROLLING_BY_INVITATIONFrench Validation of the CAPTURE Case Finding Tool for Obstructive Respiratory DiseaseNCT05654597 · 2023-04-01
TERMINATEDValidate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic DisordersNCT07646015 · 2022-10-03
COMPLETEDEvaluation of the LVivo Image Quality Scoring (IQS)NCT05563701 · 2022-09-05
COMPLETEDAntibiotic Stewardship in AECOPD Through CRP-Guided ManagementNCT05286918 · 2022-09-01
UNKNOWNRetrospective Study of Carebot AI CXR Performance in Preclinical PracticeNCT05594485 · 2022-08-15
COMPLETEDDiagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary LesionsNCT05526573 · 2022-07-14
UNKNOWNProspective, Observational Study of Wellinks Effect on COPD Hospital ReadmissionsNCT05330507 · 2022-07-05
UNKNOWNOptimizing Post-Thoracotomy Pain Management: Comparing Erector Spinae vs. Paravertebral Block in Thoracotomy PatientsNCT06964698 · 2022-06-01
COMPLETEDTo Investigate the Use of a New Syringe "Visual Pressure Control (VPC)" for Epidural Anesthesia in Children SurgeryNCT05308771 · 2022-03-25
UNKNOWN(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsNCT05241873 · 2022-03-04
TERMINATEDSitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCNCT04925986 · 2022-02-10
TERMINATEDThe Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.)NCT05299385 · 2022-01-13
UNKNOWN(HARMONY) Study of BLU-701 in EGFR-mutant NSCLCNCT05153408 · 2022-01-13
TERMINATEDStereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT SystemNCT06722885 · 2022-01-01
WITHDRAWNClinical Evaluation of ASP Health's Automated ROSE System for Bronchoscopic ApplicationsNCT05120050 · 2021-12-01
UNKNOWNCarnitine Consumption and Augmentation in Pulmonary Arterial HypertensionNCT04908397 · 2021-09-29
COMPLETEDA Clinical Study of LUNG-CT CAD Decision SupportNCT05230563 · 2021-08-19
UNKNOWNVentilation Imbalances in Mild to Moderate Chronic Obstructive Pulmonary DiseaseNCT04880551 · 2021-06-30
UNKNOWN(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCNCT04862780 · 2021-06-29
TERMINATEDAtezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)NCT04776447 · 2021-06-16
COMPLETEDImage - Navigated Resection of Lung NodulesNCT04702165 · 2021-06-03
COMPLETEDToripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid CarcinomaNCT04725448 · 2021-04-06
UNKNOWNSjogren's Lung StudyNCT04843345 · 2021-04-01
SUSPENDEDCENTR(AR): Lungs MovingNCT04711057 · 2021-04-01
COMPLETEDLung Cancer Risk and Early Detection in FirefightersNCT04614129 · 2021-03-02
COMPLETEDPost COVID-19 Pulmonary Rehabilitation ProgramNCT04982042 · 2021-03-01
UNKNOWNExternal Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLCNCT04697446 · 2020-12-01
UNKNOWNHeal-Me Personalized Online Nutrition and Exercise RoutinesNCT04666558 · 2020-11-30
COMPLETEDDaily Vitamin D for Sickle-cell Respiratory ComplicationsNCT04170348 · 2020-09-15
COMPLETEDHouston "Breathe Easy" Healthy Homes-Based Model for Multifamily Rental CommunitiesNCT05345080 · 2020-08-27
UNKNOWNCommon interventions
PlaceboDRUG13CarboplatinDRUG9PemetrexedDRUG5AeriSeal SystemDEVICE4PembrolizumabDRUG3PlaceboOTHER3Placebo oral tabletDRUG3ApatinibDRUG2CisplatinDRUG2Dry Powder InhalerDEVICE2Endobronchial UltrasoundPROCEDURE2EntinostatDRUG2GemcitabineDRUG2Low dose CTDIAGNOSTIC_TEST2Nab-PaclitaxelDRUG2osimertinibDRUG2PaclitaxelDRUG2Pulmonary RehabilitationOTHER2RalinepagDRUG2smoking cessationBEHAVIORAL2[18F]F-RESCA-EPCD6DRUG1[18F]F-RESCA-RT4DRUG1[18F]F-RESCA-T4DRUG1[68Ga]Ga-NOTA-EPCD6DRUG1[68Ga]Ga-NOTA-RT4DRUG1
Leading sponsors
National Heart, Lung, and Blood Institute (NHLBI)64University of California, San Francisco6Sichuan Cancer Hospital and Research Institute5AstraZeneca4Blueprint Medicines Corporation4University of New Mexico4Aeris Therapeutics3Brigham and Women's Hospital3Fundación GECP3Johns Hopkins Bloomberg School of Public Health3NYU Langone Health3Vanderbilt University3Columbia University2Groupe Hospitalier du Havre2Harvard Pilgrim Health Care2
Trial status mix
COMPLETED172
UNKNOWN31
TERMINATED11
RECRUITING9
WITHDRAWN6
ACTIVE_NOT_RECRUITING5
ENROLLING_BY_INVITATION5
NOT_YET_RECRUITING2
NO_LONGER_AVAILABLE1
SUSPENDED1
Phase mix
NA50
PHASE232
PHASE329
PHASE114
PHASE45
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.